137 related articles for article (PubMed ID: 9364672)
1. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice.
Cataldo DM; Van Nest G
Vaccine; 1997 Nov; 15(16):1710-5. PubMed ID: 9364672
[TBL] [Abstract][Full Text] [Related]
2. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
O'Hagan DT
Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
[TBL] [Abstract][Full Text] [Related]
3. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice.
Ou H; Yao H; Yao W; Wu N; Wu X; Han C; Cheng L; Chen K; Chen H; Li L
Vaccine; 2016 Apr; 34(20):2362-70. PubMed ID: 27013436
[TBL] [Abstract][Full Text] [Related]
5. The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.
Wu XX; Deng XL; Yu DS; Yao W; Ou HL; Weng TH; Hu CY; Hu FY; Wu NP; Yao H; Zhang FC; Li LJ
Cell Physiol Biochem; 2018; 46(2):633-643. PubMed ID: 29617693
[TBL] [Abstract][Full Text] [Related]
6. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
[TBL] [Abstract][Full Text] [Related]
7. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects.
Gasparini R; Pozzi T; Montomoli E; Fragapane E; Senatore F; Minutello M; Podda A
Eur J Epidemiol; 2001; 17(2):135-40. PubMed ID: 11599686
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.
De Donato S; Granoff D; Minutello M; Lecchi G; Faccini M; Agnello M; Senatore F; Verweij P; Fritzell B; Podda A
Vaccine; 1999 Aug; 17(23-24):3094-101. PubMed ID: 10462245
[TBL] [Abstract][Full Text] [Related]
9. Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.
Chang H; Duan J; Zhou P; Su L; Zheng D; Zhang F; Fang F; Li X; Chen Z
Microbes Infect; 2017 Dec; 19(12):616-625. PubMed ID: 28899814
[TBL] [Abstract][Full Text] [Related]
10. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
[TBL] [Abstract][Full Text] [Related]
11. Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.
Ko EJ; Lee YT; Kim KH; Jung YJ; Lee Y; Denning TL; Kang SM
J Virol; 2016 Aug; 90(15):6976-6988. PubMed ID: 27226368
[TBL] [Abstract][Full Text] [Related]
12. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
[TBL] [Abstract][Full Text] [Related]
13. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice.
Higgins DA; Carlson JR; Van Nest G
Vaccine; 1996 Apr; 14(6):478-84. PubMed ID: 8782343
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine.
Rashedi N; Taghizadeh M; Mohamadynejad P; Mahdavi M; Jalalirad R
Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):497-508. PubMed ID: 33463117
[TBL] [Abstract][Full Text] [Related]
15. The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.
Wei SH; Liu MT; Tsai YC; Liao CH; Chen CM; Wang WY; Huang YL; Chang FY; Chou P
BMC Infect Dis; 2014 Nov; 14():587. PubMed ID: 25394941
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
18. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice.
Barchfeld GL; Hessler AL; Chen M; Pizza M; Rappuoli R; Van Nest GA
Vaccine; 1999 Feb; 17(7-8):695-704. PubMed ID: 10067675
[TBL] [Abstract][Full Text] [Related]
19. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
El Sahly H
Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
[TBL] [Abstract][Full Text] [Related]
20. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.
Khurana S; Verma N; Yewdell JW; Hilbert AK; Castellino F; Lattanzi M; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2011 Jun; 3(85):85ra48. PubMed ID: 21632986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]